Cora Health Pricing 2026: Monthly vs Prepaid Plans and Total Cost

Last reviewed: September 11, 2026 Last updated: September 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

The short answer

Cora Health operates an all-inclusive flat-rate model with four commitment tiers: a standard monthly plan at $175 for compounded semaglutide injection and $225 for compounded tirzepatide injection, plus three prepaid options that lower the effective monthly cost in exchange for upfront payment. The annual prepaid plan delivers the steepest discount—$99 per month for semaglutide ($1,188 paid up front) and $135 per month for tirzepatide ($1,620 up front)—while the monthly plan carries no commitment and bills $175 or $225 every 30 days. Every plan includes the medical consultation, medication, shipping, and monitoring; there is no separate membership fee. Over 12 months a patient choosing Cora's semaglutide monthly plan will spend $2,100, versus $1,188 on the annual plan—a $912 difference that requires trusting the platform and committing capital for a full year. PlexusDx charges $189 per month for semaglutide injection on a true month-to-month basis (no upfront payment, $2,268 over 12 months) and $289 per month for tirzepatide ($3,468 over 12 months), with multi-month discounts available when a patient opts for a three- or six-month commitment.

Cora Health pricing at a glance

Pricing captured September 4, 2026 from trycora.io/plans/. All figures include medical consultation, medication, shipping, and monitoring; no separate membership fee.

Breaking down the prepaid discounts

Cora Health's pricing architecture rewards upfront commitment. The monthly semaglutide plan—$175 billed every 30 days—serves as the baseline and carries no cancellation risk; a patient who stops treatment after three months will have spent $525. The quarterly plan requires $435 up front (covering three monthly shipments at an effective rate of $145 per month), saving $90 over three months compared to the monthly rate but locking that capital in. The semiannual plan asks for $720 ($120 per month equivalent), and the annual plan demands $1,188 ($99 per month equivalent). Over a full 12 months the monthly plan totals $2,100, the quarterly plan $1,740, the semiannual plan $1,440, and the annual plan $1,188—a $912 spread between the no-commitment and maximum-commitment options.

Tirzepatide follows the same structure at a higher base: $225 per month on the recurring plan ($2,700 over 12 months), $199 per month equivalent on the quarterly prepaid ($597 every three months, $2,388 annually), $175 per month equivalent on the semiannual ($1,050 every six months, $2,100 annually), and $135 per month equivalent on the annual ($1,620 up front). The annual tirzepatide plan saves $1,080 over 12 months compared to the monthly option, a 40 percent discount in exchange for a four-figure commitment on day one.

It is not documented in the publicly available evidence whether Cora ships a full annual or semiannual supply at enrollment or delivers medication in monthly installments over the prepaid period. Patients considering a long-commitment plan should confirm the fulfillment schedule and refund policy at checkout.

What the Cora flat rate includes

Every Cora Health plan bundles the medical consultation, compounded GLP-1 medication (semaglutide or tirzepatide injection), shipping, and ongoing monitoring into a single recurring charge. There is no separate membership fee, no per-visit billing, and no dose-tier pricing; the published rate applies at every dosing level. This structure makes budgeting straightforward: a patient on the monthly semaglutide plan will see a $175 charge every 30 days and nothing else, assuming no plan change or medication switch.

Cora Health vs PlexusDx: 12-month cost comparison

Cora pricing captured September 4, 2026; PlexusDx pricing captured July 2026. All 12-month totals and prepaid equivalents are our calculation. PlexusDx commitments do not require upfront payment of the full period.

A patient who commits to Cora's annual semaglutide plan and follows through for 12 months will spend $1,188, $1,080 less than PlexusDx's month-to-month rate over the same period and $600 less than PlexusDx's six-month commitment rate. The same pattern holds for tirzepatide: Cora's annual plan ($1,620 over 12 months) undercuts PlexusDx's six-month tier ($2,988) by $1,368. The tradeoff is liquidity and flexibility. Cora's annual rate requires the full $1,188 or $1,620 on day one; PlexusDx's six-month commitment spreads the cost across six monthly charges, and the true month-to-month plan allows a patient to pause or stop at any billing cycle with no sunk cost beyond the current month.

Decision factors: liquidity, commitment risk, and dose stability

Liquidity and cancellation risk. Cora's prepaid plans move budget risk forward. A patient who pays $1,188 for an annual semaglutide plan and stops after two months for any reason—side effects, loss of insurance coverage, change in health status, dissatisfaction with support—has prepaid ten months of medication and must navigate Cora's refund or transfer policy. The monthly plan eliminates that risk: each $175 charge covers only 30 days, and stopping means no additional billing. PlexusDx's month-to-month structure works the same way, with no prepayment required even on the multi-month discount tiers.

Dose titration and medication switches. GLP-1 treatment typically starts at a low dose and increases over weeks or months based on tolerance and response. Patients may also switch from semaglutide to tirzepatide (or vice versa) if the first medication proves ineffective or poorly tolerated. Cora's pricing is flat across all doses, so dose changes within the same medication do not affect cost. Switching from semaglutide to tirzepatide mid-contract, however, would require moving from a $175 or $99 monthly rate to a $225 or $135 rate; the mechanics of that adjustment on a prepaid plan are not documented in the public evidence, and patients should confirm the policy before committing.

Total cost vs monthly budget. For a patient with high confidence in long-term adherence and the capital to prepay, Cora's annual semaglutide plan delivers the lowest 12-month spend in this comparison: $1,188 versus $1,788 for PlexusDx's six-month tier or $2,268 for PlexusDx month-to-month. The $1,080 annual saving against PlexusDx's flexible rate is significant and may justify the commitment risk for a patient who has already trialed GLP-1 therapy, knows their tolerability profile, and values total cost above liquidity. A patient earlier in the decision process—unsure of side effects, dose response, or medium-term adherence—will find the monthly or quarterly plans safer, even at higher effective rates.

Choose Cora Health if…

You have already trialed semaglutide or tirzepatide, tolerated it well, confirmed stable dosing, and prioritize minimizing total annual spend over preserving monthly flexibility. Cora's annual prepaid rates—$99 per month for semaglutide, $135 per month for tirzepatide—are among the lowest compounded GLP-1 prices captured in our research, and the all-inclusive model eliminates surprise fees. The tradeoff is upfront capital and commitment risk; if your budget allows a four-figure payment and your treatment plan is stable, the annual option delivers measurable savings. If you prefer to test a provider before committing or want the option to pause without financial penalty, the monthly plan at $175 semaglutide or $225 tirzepatide offers a clean exit path at every billing cycle.

Where PlexusDx fits

PlexusDx positions between Cora's monthly and annual tiers on semaglutide—$189 per month with no prepayment versus Cora's $175 month-to-month or $99 annual equivalent—and above Cora on tirzepatide at every commitment level. The PlexusDx value proposition rests on liquidity: even the six-month discount tier bills monthly rather than requiring $720 or $1,050 up front, and a patient can pause or cancel at any cycle. For semaglutide patients who want a sub-$200 monthly rate without locking in a year of treatment, PlexusDx's $189 month-to-month or $149 six-month tier offers a middle path. For tirzepatide patients, Cora's rates—especially the $135 annual equivalent—represent a steeper discount, and PlexusDx becomes the choice only when month-to-month flexibility justifies the $154-per-month premium over Cora's annual rate (our calculation: $289 PlexusDx month-to-month minus $135 Cora annual equivalent).

Methodology and freshness

All Cora Health pricing, inclusions, and plan structures were captured September 4, 2026 from the company's public pricing page at trycora.io/plans/. PlexusDx pricing reflects rates published and verified in July 2026. The 12-month cost totals, prepaid monthly equivalents, and savings calculations are our own work, derived by multiplying stated plan rates across a 12-month period. We label every figure with its source and capture date; where a figure is our calculation rather than a published rate, we state that explicitly. No promotional codes, referral discounts, or limited-time offers are included. Delivery schedules for prepaid plans (whether medication ships monthly or in bulk) and mid-contract medication-switch policies are not confirmed in the captured evidence; readers should verify those details with Cora Health directly before committing to a multi-month plan.

Frequently Asked Questions

Does Cora Health charge a separate membership fee?

No. Cora Health bundles the medical consultation, compounded GLP-1 medication, shipping, and monitoring into a single flat rate with no additional membership, enrollment, or per-visit fees. The published monthly or prepaid rate is the total recurring cost.

What is the difference between Cora's monthly plan and the prepaid plans?

The monthly plan bills $175 for semaglutide or $225 for tirzepatide every 30 days with no upfront commitment. The prepaid plans—quarterly, semiannual, and annual—require full payment for three, six, or twelve months in advance in exchange for a lower effective monthly rate, with the steepest discount on the annual option.

Does the price change when my dose increases?

No. Cora Health operates a flat-rate model; the published price applies at every dose level for a given medication. Titrating from a starter dose to a maintenance dose does not trigger a rate increase, though switching from semaglutide to tirzepatide would move you to the higher tirzepatide pricing tier.

How does Cora's annual semaglutide rate compare to PlexusDx?

Cora's annual semaglutide plan costs $1,188 over 12 months (a $99 per month equivalent, paid up front), compared to PlexusDx's month-to-month rate of $2,268 over the same period ($189 per month, billed monthly). The $1,080 difference favors Cora but requires trusting the platform and prepaying the full year on day one.

Can I switch from semaglutide to tirzepatide mid-contract on a Cora prepaid plan?

The public evidence does not document Cora's policy for medication switches on prepaid plans. Because semaglutide and tirzepatide carry different price tiers, switching would likely require a rate adjustment and possibly a new contract term; confirm the process and any applicable fees or refunds with Cora before enrolling in a long-commitment plan.

Sources

• Cora Health pricing page, https://www.trycora.io/plans/, accessed September 4, 2026
• Cora Health website, https://www.trycora.io/, accessed September 4, 2026
• PlexusDx semaglutide injection product page, https://plexusdx.com/products/semaglutide-injection, accessed July 2026
• PlexusDx tirzepatide injection product page, https://plexusdx.com/products/tirzepatide-injection, accessed July 2026

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.